人黑色素瘤细胞系M14
BLUEFBIO™ Product Sheet
细胞名称 |
人黑色素瘤细胞系M14 |
||
货物编码 |
BFN60808843 |
||
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
细胞数量 |
1x10^6 |
1x10^6 |
|
保存温度 |
37℃ |
-198℃ |
|
运输方式 |
常温保温运输 |
干冰运输 |
|
安全等级 |
1 |
||
用途限制 |
仅供科研 3类 |
培养体系 |
90%DMEM+10%FBS+1%三抗 |
||
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
简介 |
人黑色素瘤细胞系M14取自33岁男性供体。贴壁培养。 |
||
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: MD Anderson Cell Lines Project. Part of: NCI-60 cancer cell line panel. Doubling time: 26.3 hours (NCI-DTP). Microsatellite instability: Stable (MSS) (Sanger). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep proteome analysis. Omics: DNA methylation analysis. Omics: Fluorescence phenotype profiling. Omics: lncRNA expression profiling. Omics: Metabolome analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. |
||
基因突变 |
Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=12068308; PubMed=17088437; PubMed=19799798; PubMed=29492214). Heterozygous for CDKN2A c.150+2T>C (IVS1+2T>C); splice donor mutation and c.455insCdel26 (PubMed=19799798; PubMed=29492214). Heterozygous for TP53 p.Gly266Glu (c.797G>A) (ClinVar=VCV000161516) (PubMed=17088437; PubMed=18277095). |
||
HLA信息 |
Class I HLA-A A*11:01:01,24:02:01 HLA-B B*15,35 HLA-C C*03:03:01,04 Class II HLA-DP DPB1*13:01,19:01 HLA-DQ DQB1*03:02,06:03 HLA-DR DRB1*04:05:01,13:01:01 |
||
STR信息 |
Amelogenin X CSF1PO 11 D1S1656 11,12 D2S441 11,14 D2S1338 19,24 D3S1358 14,16 D5S818 11,12 D7S820 8,10 D8S1179 13 D10S1248 14 D12S391 18,19 D13S317 12 D16S539 9,13 D18S51 13,17 D19S433 14,15 D21S11 30 D22S1045 15 FGA 21 SE33 15,22 TH01 6,7 TPOX 8,11 vWA 16,18 |
||
参考文献 |
PubMed=27807467; DOI=10.1186/s13100-016-0078-4 Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H. A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob. DNA 7:20-20(2016)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017)
PubMed=28940260; DOI=10.1002/ijc.31067 Korch C., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L., Kniss D., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A. Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. Int. J. Cancer 142:561-572(2017)
PubMed=29492214; DOI=10.18632/oncotarget.23989 Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G. Genetic alterations in main candidate genes during melanoma progression. Oncotarget 9:8531-8541(2018)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) |